Verenium Reports Financial Results for the Third Quarter and Nine Months Ended Septembe...(byDanisco Animal Nutrition which continu...),Health

Date:11/6/2007

by Danisco Animal Nutrition, which continues to expand its global phytase market share position in the animal feed industry. Verenium currently manufactures Phyzyme through a third-party manufacturing arrangement and maintains a product profit-sharing agreement with Danisco for all Phyzyme sales. The Company also experienced sales growth for its other enzyme products, including Quantum(TM) Phytase and Fuelzyme(TM)-LF. Total revenues decreased for the 2007 quarter and year-to-date periods, as the increase in product revenues was more than offset by a decrease in collaborative revenues primarily related to the Company's previously-announced restructuring of its collaboration agreement with Syngenta.

Product gross profit (product revenues less cost of product revenues) and product gross margin (product gross profit divided by product revenues) improved in the third quarter and first nine months of 2007 versus comparable periods last year due primarily to growth in Phyzyme sales which resulted, in part, from efforts by Danisco Animal Nutrition to introduce a new thermally- stable formulation of Phyzyme and grow its European Phyzyme business following the recent expanded approval within the European Union. Over time, the Company believes that product volume growth in Phyzyme and other products in the Company's portfolio should result in more stable and sustainable improvement in both product gross profit and product gross margin.

Research and development expenses were higher in the third quarter and year-to-date periods of 2007 versus 2006 primarily related to the incremental operating expenses associated with the Celunol business since the June 2007 merger. Selling, general and administrative expenses for the 2007 periods were higher than 2006 due primarily to the inclusion of incremental Celunol operating expenses since June 2007, as well as one-time expenses related to the merger.

In connection with the merger with Celunol, the Company recorded a pre
'/>"/>

SOURCE Verenium Corporation Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.